WO2017152144A8 - Immunisation d'essaim par des enveloppes de ch505 - Google Patents

Immunisation d'essaim par des enveloppes de ch505 Download PDF

Info

Publication number
WO2017152144A8
WO2017152144A8 PCT/US2017/020821 US2017020821W WO2017152144A8 WO 2017152144 A8 WO2017152144 A8 WO 2017152144A8 US 2017020821 W US2017020821 W US 2017020821W WO 2017152144 A8 WO2017152144 A8 WO 2017152144A8
Authority
WO
WIPO (PCT)
Prior art keywords
envelopes
swarm
hiv
immunization
swarm immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/020821
Other languages
English (en)
Other versions
WO2017152144A1 (fr
Inventor
Barton F. Haynes
Mattia Bonsignori
Hua-Xin Liao
Bette T. Korber
Peter T. HRABER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Los Alamos National Security LLC
Duke University
Original Assignee
Los Alamos National Security LLC
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Alamos National Security LLC, Duke University filed Critical Los Alamos National Security LLC
Publication of WO2017152144A1 publication Critical patent/WO2017152144A1/fr
Publication of WO2017152144A8 publication Critical patent/WO2017152144A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Selon certains aspects, l'invention concerne des immunogènes du VIH-1, y compris des enveloppes du VIH-1 CH505 et des sélections de ces dernières, ainsi que des méthodes d'immunisations d'essaims à l'aide de combinaisons d'enveloppes de VIH-1.
PCT/US2017/020821 2016-03-03 2017-03-03 Immunisation d'essaim par des enveloppes de ch505 Ceased WO2017152144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303248P 2016-03-03 2016-03-03
US62/303,248 2016-03-03

Publications (2)

Publication Number Publication Date
WO2017152144A1 WO2017152144A1 (fr) 2017-09-08
WO2017152144A8 true WO2017152144A8 (fr) 2017-10-19

Family

ID=59743283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/020821 Ceased WO2017152144A1 (fr) 2016-03-03 2017-03-03 Immunisation d'essaim par des enveloppes de ch505

Country Status (1)

Country Link
WO (1) WO2017152144A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254360B (it) * 1992-05-11 1995-09-14 San Romanello Centro Fond Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
FR2806912B1 (fr) * 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
WO2016014721A2 (fr) * 2014-07-22 2016-01-28 Duke University Compositions comprenant des enveloppes sensibles au virus ch505

Also Published As

Publication number Publication date
WO2017152144A1 (fr) 2017-09-08

Similar Documents

Publication Publication Date Title
WO2018161049A8 (fr) Compositions et procédés pour induire des anticorps anti-vih-1
WO2017152146A3 (fr) Compositions et procédés pour induire des anticorps du vih-1
WO2017151801A8 (fr) Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235
WO2018109170A3 (fr) Anticorps il-11ra
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
MX2019007020A (es) Anticuerpos il-11.
WO2015168019A3 (fr) Conjugués médicament-anticorps anti-ptk7
CA3296120A1 (en) Objective achievement portfolio generating device, program, and method
IL266131A (en) Compositions for reprogramming cells into dendritic cells or antigen-presenting cells, methods and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
WO2016198932A3 (fr) Compositions de nanoparticules pour thérapie prolongée
WO2016105450A3 (fr) Anticorps trispécifiques
WO2015197823A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
WO2015179658A3 (fr) Immunoconjugués et anticorps anti-gpc3
USD792319S1 (en) Anchor
WO2016097370A3 (fr) Anticorps antagonistes anti-axl
WO2015164392A8 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
WO2016138091A3 (fr) Procédés de sélection de lymphocytes t génétiquement modifiés
MX2017009937A (es) Cepas fungicas y metodos de uso.
PH12022550450A1 (en) Anti-htra1 antibodies and methods of use thereof
WO2017156495A8 (fr) Composés et procédés pour moduler la tyrosine kinase de bruton
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
WO2018138681A9 (fr) Anticorps spécifiques de l'hémagglutinine et leurs utilisations
WO2015139020A3 (fr) Compositions vaccinales et méthodes pour rétablir la fonction de la voie nkg2d contre les cancers

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17760959

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17760959

Country of ref document: EP

Kind code of ref document: A1